Lian Li

Lian Li

Auto-generated profile, based on publicly available information

Lian Li

Department of Epidemiology, Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2020 in Global Health Action
Verified
Journal Article
Open access
LLLian Li
Lian Li
NSNing Sun
Ning Sun
LZLina Zhang
Lina Zhang
GXGuodong Xu
Guodong Xu
JLJingjing Liu
Jingjing Liu
LHLiyuan Han
Liyuan Han
Most countries worldwide, especially low- and middle-income countries (LMICs), are facing an increasing prevalence of fast-food consumption and multiple burdens of malnutrition among young adolesce...

22 April 2020 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
JHJingcen Hu
Jingcen Hu
HZHong Zhu
Hong Zhu
GXGuodong Xu
Guodong Xu
ZCZhu Chen
Zhu Chen
LLLian Li
Lian Li
ZSZhisen Shen
Zhisen Shen
Objective: DHFR encodes dihydrofolate reductase, a major enzyme in the metabolism of folate, and is a candidate gene for ischemic stroke (IS). Therefore, we aimed to investigate the association between DHFR promoter methylation and IS in a Chinese population with primary hypertension. Methods: Quantitative methylation‐specific PCR was used to measure the level of DHFR promoter methylation. A multivariate logistic regression model was used to investigate the association between DHFR promoter methylation and IS. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic value of DHFR promoter methylation for IS. Results: The level of methylation of the DHFR promoter in the IS group was significantly lower than that in the hypertensive group (median [interquartile range]: 9.11 [2.81‐16.20] vs 24.94 [7.16‐56.45], P < .001). DHFR promoter methylation and homocysteine (Hcy) levels were both related to IS, with an ORs (95% CI) of 0.976 (0.967‐0.984) and 1.057 (1.027‐1.108), respectively. The areas under the curve for the diagnosis of DHFR promoter hypomethylation in IS were 0.603 (95% CI, 0.527‐0.678) in men and 0.754 (95% CI, 0.693‐0.815) in women. A dual‐luciferase reporter assay revealed that the target sequence in the DHFR promoter upregulated gene expression. Conclusion: There is a significant association between methylation of the DHFR promoter and IS in this Chinese hypertensive population. Hypomethylation of the DHFR promoter may serve as a novel marker for the diagnosis of IS in women.

1 January 2020 in Journal of Research in Medical Sciences
Verified
Journal Article
Open access
PDF file
ZSZhisen Shen
Zhisen Shen
LHLiyuan Han
Liyuan Han
GXGuodong Xu
Guodong Xu
ZWZhiyi Wang
Zhiyi Wang
LLLian Li
Lian Li
CWChangyi Wang
Changyi Wang
Background: DNA methylation was considered to play an important role in hypertension. However, the direct association between dihydrofolate reductase (DHFR) promoter methylation and hypertension remains unclear. We thus aimed to investigate the relationship between DNA methylation of DHFR promoter and hypertension. Materials and Methods: A total of 371 hypertensive patients (diastolic blood pressure ≥90 mmHg and/or systolic blood pressure ≥140 mmHg or a history of antihypertensive treatment) and 320 age- and sex-matched healthy controls from the Hypertension Management Information System in Nanshan Community Health Service Centers were included in this case–control study. Quantitative methylation-specific polymerase chain reaction was used to measure the level of DHFR promoter methylation, which was presented as the percentage of methylated reference (PMR). A multivariate logistic regression model was used to explore the risk of DHFR promoter methylation. Results: Our results indicated that the level of DHFR promoter methylation was higher in hypertensive patients (median PMR, 34.32%; interquartile range, 11.34–119.60) than in healthy controls (median PMR, 18.45%; interquartile range, 8.16–35.40) (P < 0.001). Multivariable analysis showed that the risk of DHFR promoter hypermethylation was significantly higher in hypertensive patients than in healthy controls (odds ratio = 3.94, 95% confidence interval = 2.56–6.02, P < 0.001). Furthermore, hypermethylation was positively associated with sex, high blood homocysteine levels, and alcohol drinking. In particular, the area under the receiver operating characteristic curve was 0.688 (0.585–0.668) for the male hypertensive patients, suggesting the potential diagnostic value of DHFR promoter methylation in male hypertension. Conclusion: Our results demonstrated that DHFR promoter hypermethylation is positively associated with the risk of hypertension in Chinese.